PA8777901A1 - "derivados de quinolina -carboxamida en calidad de antagonistas de p2y12" - Google Patents

"derivados de quinolina -carboxamida en calidad de antagonistas de p2y12"

Info

Publication number
PA8777901A1
PA8777901A1 PA20088777901A PA8777901A PA8777901A1 PA 8777901 A1 PA8777901 A1 PA 8777901A1 PA 20088777901 A PA20088777901 A PA 20088777901A PA 8777901 A PA8777901 A PA 8777901A PA 8777901 A1 PA8777901 A1 PA 8777901A1
Authority
PA
Panama
Prior art keywords
compounds
adp
receiver
formula
antagonists
Prior art date
Application number
PA20088777901A
Other languages
English (en)
Spanish (es)
Inventor
Nazare Marc
Hessler Gerhard
Joerg Czech Dr
Zech Gernot
Just Melitta
Weiss Tilo
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38462433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8777901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8777901A1 publication Critical patent/PA8777901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PA20088777901A 2007-04-23 2008-04-23 "derivados de quinolina -carboxamida en calidad de antagonistas de p2y12" PA8777901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07008209 2007-04-23

Publications (1)

Publication Number Publication Date
PA8777901A1 true PA8777901A1 (es) 2008-11-19

Family

ID=38462433

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088777901A PA8777901A1 (es) 2007-04-23 2008-04-23 "derivados de quinolina -carboxamida en calidad de antagonistas de p2y12"

Country Status (18)

Country Link
US (1) US8669266B2 (enExample)
EP (1) EP2148871A1 (enExample)
JP (1) JP5309131B2 (enExample)
KR (1) KR20100015886A (enExample)
CN (1) CN101663293B (enExample)
AR (1) AR066225A1 (enExample)
AU (1) AU2008241091B2 (enExample)
BR (1) BRPI0810462A2 (enExample)
CA (1) CA2684644A1 (enExample)
CL (1) CL2008001157A1 (enExample)
IL (1) IL201620A (enExample)
MX (1) MX2009011089A (enExample)
MY (1) MY153427A (enExample)
PA (1) PA8777901A1 (enExample)
PE (1) PE20090241A1 (enExample)
TW (1) TW200848042A (enExample)
UY (1) UY31039A1 (enExample)
WO (1) WO2008128647A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002235694B2 (en) 2001-02-28 2007-06-14 Covalon Technologies Inc. Method of making anti-microbial polymeric surfaces
WO2009082526A2 (en) * 2007-10-05 2009-07-02 Pharmacopeia, Inc. Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
TWI361690B (en) 2007-11-29 2012-04-11 Actelion Pharmaceuticals Ltd Phosphonic acid derivatives
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
WO2010116328A2 (en) * 2009-04-08 2010-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
EP2421859B1 (en) 2009-04-22 2014-04-09 Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as p2y12 receptor antagonists
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 ３−（ビアリールオキシ）プロピオン酸誘導体
AR079451A1 (es) * 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
CN103857288B (zh) 2011-03-04 2016-09-21 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的氨基-喹啉
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
CN102584852B (zh) * 2011-12-30 2014-08-13 厦门大学 真菌代谢产物桥南霉素及其制备方法和应用
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
EP2725025A1 (fr) * 2012-10-26 2014-04-30 Sanofi Dérives de 1H-indole-3-carboxamide et leurs utilisation comme antagonistes du P2Y12
EP2958911B1 (en) 2013-02-21 2017-10-18 GlaxoSmithKline Intellectual Property Development Limited Quinazolines as kinase inhibitors
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
DE102015217396B4 (de) 2014-09-11 2018-07-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. System, insbesondere System zur Eingabesteuerung für eine Arbeitshilfe
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
US10730868B2 (en) * 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
KR102510832B1 (ko) 2017-03-15 2023-03-15 이도르시아 파마슈티컬스 리미티드 P2y12 수용체 안타고니스트의 피하 투여
CN107648607A (zh) * 2017-09-11 2018-02-02 南昌大学 嘌呤2y12受体拮抗剂在制备糖尿病神经病理损伤疾病药物中的应用
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
WO2023108363A1 (en) * 2021-12-13 2023-06-22 Beijing Honghui Meditech Co., Ltd Pyrimidine-annulated triazole derivatives and their use in platelet aggregation inhibition
CN115429874A (zh) * 2022-09-20 2022-12-06 暨南大学 水蛭素靶向并抑制dpp4治疗糖尿病

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
SI1427415T1 (sl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa
KR20050085580A (ko) * 2002-12-11 2005-08-29 쉐링 악티엔게젤샤프트 혈소판 아데노신 디포스페이트 수용체 길항제로서의2-아미노카르보닐-퀴놀린 화합물
MXPA06000675A (es) 2003-07-24 2006-04-19 Astellas Pharma Inc Derivado de quinolona o sal del mismo.
US7157445B2 (en) * 2004-02-26 2007-01-02 Aventis Pharma S.A. Administration of enoxaparin sodium to patients with severe renal impairment
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.

Also Published As

Publication number Publication date
WO2008128647A1 (en) 2008-10-30
AU2008241091B2 (en) 2013-05-09
JP5309131B2 (ja) 2013-10-09
CN101663293B (zh) 2013-07-31
US8669266B2 (en) 2014-03-11
KR20100015886A (ko) 2010-02-12
HK1141803A1 (en) 2010-11-19
PE20090241A1 (es) 2009-04-03
CN101663293A (zh) 2010-03-03
MY153427A (en) 2015-02-13
IL201620A (en) 2013-11-28
CA2684644A1 (en) 2008-10-30
CL2008001157A1 (es) 2008-11-03
JP2010524984A (ja) 2010-07-22
BRPI0810462A2 (pt) 2014-10-14
MX2009011089A (es) 2009-10-30
AU2008241091A1 (en) 2008-10-30
EP2148871A1 (en) 2010-02-03
UY31039A1 (es) 2008-11-28
TW200848042A (en) 2008-12-16
AR066225A1 (es) 2009-08-05
US20100135999A1 (en) 2010-06-03
IL201620A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
PA8777901A1 (es) "derivados de quinolina -carboxamida en calidad de antagonistas de p2y12"
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
CO6450668A2 (es) 3h-imidazol[4,5-c]piridina-6-carboxamidas en calidad de agentes antiinflamatorios
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
UY31524A1 (es) Nuevos compuestos 010
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
UY30327A1 (es) Nuevos compuestos ii
DOP2008000060A (es) Compuestos novedosos como ligandos del receptor de canabinoides y usos de los mismo.
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
UY30460A1 (es) Compuestos terapéuticos
MX2009013131A (es) Moduladores de gamma secretasa.
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid